Latest Melanotan II Stories
CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 12/952,238 (the '238 application). The application includes...
TAMPA, Fla., Feb. 14, 2013 /PRNewswire-iReach/ -- US Peptides is a United States based provider of peptides for research purposes. Peptides are short polymers of amino acid monomers linked together by peptide bonds. (Photo: http://photos.prnewswire.com/prnh/20130214/CG59885) Research peptides are used around the world for a number of reason but most notably to test the effects of growth hormone related hormones and growth hormone related peptides and their effects. US Peptides...
LARGO, Fla., Feb. 5, 2013 /PRNewswire-iReach/ -- US Peptides is a United States based provider of peptides for research purposes. Peptides are short polymers of amino acid monomers linked together by peptide bonds. (Photo: http://photos.prnewswire.com/prnh/20130205/CG54517) Research peptides are used around the world for a number of reasons but most notably to test the effects of growth hormone related hormones and growth hormone related peptides and their effects. US Peptides...
LARGO, Fla., Jan. 29, 2013 /PRNewswire-iReach/ -- Bacteriostatic water is a sterile water solution used for injection purposes. The difference between Bacteriostatic water and sterile water is that bacteriostatic water contains .09% benzyl alcohol added as a bacteriostatic preservative and sterile water does not. (Photo: http://photos.prnewswire.com/prnh/20130129/CG50189) The bacteriostatic preservative prevents the growth or reproducing of bacteria within the vial. According to...
LARGO, Fla., Jan. 15, 2013 /PRNewswire-iReach/ -- US Peptides is a United States based provider of peptides for research purposes. Peptides are short polymers of amino acid monomers linked together by peptide bonds. (Photo: http://photos.prnewswire.com/prnh/20130115/CG41912) Research peptides are used around the world for a number of reason but most notably to test the effects of growth hormone related hormones and growth hormone related peptides and their effects. Research...
Leading seller of research quality peptides like IGF-1 is now offering discount off research peptide hormone purchases. Tampa, FL (PRWEB) December 01, 2012 US Peptides is a United States based provider of peptides for research purposes. Peptides are short polymers of amino acid monomers linked together by peptide bonds. Research peptides are used around the world for a number of reason but most notably to test the effects of growth hormone related hormones and growth hormone related...
CRANBURY, N.J., June 28, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced today that enrollment of patients has commenced in Palatin's Phase 2b clinical trial evaluating the efficacy and safety of bremelanotide (previously called PT-141), an on-demand, first-in-class melanocortin agonist being developed for the treatment of female sexual dysfunction (FSD). The multicenter study is a placebo-controlled, randomized, parallel group, dose-finding trial that will test...
CRANBURY, N.J., June 15, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications, announced presentation and publication of a report on validation of a scale for subjective male sexual arousal. The underlying study was supported by grants from Palatin. Michael A. Perelman, Ph.D., of the New York Presbyterian Hospital and the Weill Medical College of Cornell University, presented the poster on...
CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of...
CRANBURY, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without blood pressure side effects. Based on the...
